Currently, therapeutic strategies for dHMN associated with SIGMAR1 gene mutations remain in the investigational phase, with management primarily focused on improving quality of life and slowing disease progression (Frasquet and Sevilla, 2022). The gene discussed is SIGMAR1; the disease is distal hereditary motor neuropathy.